Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 8;13(3):436.
doi: 10.3390/v13030436.

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Monika Maria Biernat  1 , Anna Kolasińska  1 , Jacek Kwiatkowski  1 , Donata Urbaniak-Kujda  1 , Paweł Biernat  2 , Justyna Janocha-Litwin  3 , Małgorzata Szymczyk-Nużka  4 , Dawid Bursy  2 , Elżbieta Kalicińska  1 , Krzysztof Simon  3 , Grzegorz Mazur  5 , Tomasz Wróbel  1
Affiliations

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Monika Maria Biernat et al. Viruses. .

Abstract

The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48-72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma-treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.

Keywords: COVID-19; convalescent plasma; hematological malignancies.

PubMed Disclaimer

Conflict of interest statement

K.S. received consultancy honoraria, speaker fees, or research support from Roche, Gilead, Bayer, Abbvie, Intercept, Tobira, GSK, Janssen, MSD, BMS and Pfizer outside the submitted work. The remaining authors declare no competing financial interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Kaplan–Meier analysis of hematological patients with COVID-19 who received convalescent plasma compared with patients from a historical group treated with other therapy (remdesivir, tocilizumab, hydroxychloroquine, lopinavir/ritonavir). Hazard ratio (HR) and 95% CI are calculated from a Cox model without covariates.
Figure 2
Figure 2
The PCA analysis presented in the pca1 vs. pca2 load diagram. Analysis of the effect of applied early plasma therapy on the course of COVID-19 in hematological patients using generalized principal component analysis PCA. The PCA model was estimated using the NIPALS iterative algorithm, the convergence criterion was set at the level of 0.00001, setting the maximum number of iterations at 50. The number of components was determined by determining the maximum predictive capability Q^2 using the V-fold cross-validation method, setting the maximum number of components at the level of V_max = 7. The obtained optimal PCA model was finally reduced to 2 components.
See this image and copyright information in PMC

References

    1. Biernat M.M., Zińczuk A., Biernat P., Bogucka-Fedorczuk A., Kwiatkowski J., Kalicińska E., Marciniak D., Simon K., Wróbel T. Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit-High mortality rate in infected patients with haematologic malignancies. J. Clin. Virol. 2020;130:104574. doi: 10.1016/j.jcv.2020.104574. - DOI - PMC - PubMed
    1. Vijenthira A., Gong I.Y., Fox T.A., Booth S., Cook G., Fattizzo B., Martín-Moro F., Razanamahery J., Riches J.C., Zwicker J.I., et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. doi: 10.1182/blood.2020008824. - DOI - PMC - PubMed
    1. Lee L.Y.W., Cazier J.-B., Angelis V., Arnold R., Bisht V., Campton N.A., Chackathayil J., Cheng V.W., Curley H.M., Fittall M.W., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet. 2020;395:1919–1926. doi: 10.1016/S0140-6736(20)31173-9. - DOI - PMC - PubMed
    1. Zarifkar P., Kamath A., Robinson C., Morgulchik N., Shah S., Cheng T., Dominic C., Fehintola A., Bhalla G., Ahillan T., et al. Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: A Systematic Review and Meta-analysis. Clin. Oncol. 2021;33:e180–e191. doi: 10.1016/j.clon.2020.11.006. - DOI - PMC - PubMed
    1. Salazar E., Perez K.K., Ashraf M., Chen J., Castillo B., Christensen P.A., Eubank T., Bernard D.W., Eagar T.N., Long S.W., et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am. J. Pathol. 2020;190:1680–1690. doi: 10.1016/j.ajpath.2020.05.014. - DOI - PMC - PubMed

Publication types

LinkOut - more resources